Life-changing' cystic fibrosis drugs approved for use in younger children
Two drugs for cystic fibrosis have been authorized for use in younger patients, extending their licenses to include babies, toddlers, and reception-aged children.
Kaftrio can now be offered to children aged two to five, while Kalydeco can be given to babies as young as one month old.
The drugs target the underlying cause of the disease and can improve lung function, offering hope to younger patients with cystic fibrosis. [ more ]